Display options
Cite
Xu L, Qiu Y, Li Y, et al. Tissue dynamics of von Willebrand factor characterized by a novel fluorescent protein-von Willebrand factor chimera. J Thromb Haemost. 2021;doi: 10.1111/jth.15542.
Xu, L., Qiu, Y., Li, Y., Wei, Y., Wan, Y., & Deng, W. (2021). Tissue dynamics of von Willebrand factor characterized by a novel fluorescent protein-von Willebrand factor chimera. Journal of thrombosis and haemostasis : JTH, . https://doi.org/10.1111/jth.15542
Xu, Linru, et al. "Tissue dynamics of von Willebrand factor characterized by a novel fluorescent protein-von Willebrand factor chimera." Journal of thrombosis and haemostasis : JTH vol. (2021). doi: https://doi.org/10.1111/jth.15542
Xu L, Qiu Y, Li Y, Wei Y, Wan Y, Deng W. Tissue dynamics of von Willebrand factor characterized by a novel fluorescent protein-von Willebrand factor chimera. J Thromb Haemost. 2021 Sep 30; doi: 10.1111/jth.15542. Epub 2021 Sep 30. PMID: 34592034.
Copy Download .nbib Format: NLM
Share it on

J Thromb Haemost. 2021 Sep 30; doi: 10.1111/jth.15542. Epub 2021 Sep 30.

Tissue dynamics of von Willebrand factor characterized by a novel fluorescent protein-von Willebrand factor chimera.

Journal of thrombosis and haemostasis : JTH

Linru Xu, Yanyang Qiu, Yanqing Li, Yaxuan Wei, Yan Wan, Wei Deng

Affiliations

  1. Cyrus Tang Medical Institute and Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.

PMID: 34592034 DOI: 10.1111/jth.15542

Abstract

BACKGROUND: Tissue dynamics of von Willebrand factor (VWF) that are vital to its biological function have not been fully characterized.

OBJECTIVE: To develop a new fluorescent protein--VWF chimera (FP-VWF) that has similar hematologic function to wild-type VWF and use it to monitor the tissue dynamics of VWF distribution.

METHODS: Genotyping, platelet counting, tail bleeding time assay, agarose gels, western blot, platelet aggregation, proteolytic analysis, and ELISA were applied in characterizing the function of FP-VWF; fluorescence spectrometer and confocal fluorescence microscope were used to monitor the plasma and tissue distribution of FP-VWF.

RESULTS: The transgenic mice that carry the FP-VWF retain hematologic activity of VWF with plasma levels of FP-VWF reduced by 50% and there are reduced high molecular weight FP-VWF multimers compared to the wild-type mice. The GPIb-binding and ADAMTS-13 (A Disintegrin and Metalloprotease with ThrombSpondin type 1 motif, member 13) proteolytic efficiency of FP-VWF are similar to wild-type VWF. The tissue distribution of FP-VWF was probed directly through its intrinsic fluorescence at normal or stimulated status, which indicated that the medicine-stimulated endogenous FP-VWF seems primarily released from the aorta and cleared in the spleen. Similar results were observed in non-fluorescent mice through a standard immunofluorescence approach. The fluorescence signals of FP-VWF were also similar to the standard dye-based approach in detecting the FeCl

CONCLUSIONS: Together, these results suggest that this novel FP-VWF chimera is valuable in probing the tissue dynamics of VWF in quite a few biological and pharmaceutical applications.

© 2021 International Society on Thrombosis and Haemostasis.

Keywords: chimera; desmopressin; thrombosis; tissue distribution; von Willebrand factor

References

  1. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973;52:2708-2716. doi:10.1172/JCI107465 - PubMed
  2. Sarji KE, Stratton RD, Wagner RH, Brinkhous KM. Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc Natl Acad Sci USA. 1974;71:2937-2941. doi:10.1073/pnas.71.8.2937 - PubMed
  3. De Marco L, Girolami A, Russell S, Ruggeri ZM. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest. 1985;75:1198-1203. doi:10.1172/JCI111816 - PubMed
  4. Bauer AT, Suckau J, Frank K, et al. von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 2015;125:3153-3163. doi:10.1182/blood-2014-08-595686 - PubMed
  5. Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018;132:141-147. doi:10.1182/blood-2018-02-769000 - PubMed
  6. Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham offspring study. Circulation. 2008;118:2533-2539. doi:10.1161/CIRCULATIONAHA.108.792986 - PubMed
  7. Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017;15:1285-1294. doi:10.1111/jth.13696 - PubMed
  8. Luo GP, Ni B, Yang X, Wu YZ. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 2012;128:158-169. doi:10.1159/000339426 - PubMed
  9. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117:1449-1459. doi:10.1161/CIRCULATIONAHA.107.722827 - PubMed
  10. Yang AJ, Wang M, Wang Y, et al. Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. Oncogenesis. 2018;7:12. doi:10.1038/s41389-017-0023-5 - PubMed
  11. Buchwalow I, Samoilova V, Boecker W, Tiemann M. Non-specific binding of antibodies in immunohistochemistry: fallacies and facts. Sci Rep. 2011;1:28. doi:10.1038/srep00028. - PubMed
  12. Romani de Wit T, Rondaij MG, Hordijk PL, Voorberg J, van Mourik JA. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23:755-761. doi:10.1161/01.ATV.0000069847.72001.E8 - PubMed
  13. Hannah MJ, Skehel P, Erent M, Knipe L, Ogden D, Carter T. Differential kinetics of cell surface loss of von Willebrand factor and its propolypeptide after secretion from Weibel-Palade bodies in living human endothelial cells. J Biol Chem. 2005;280:22827-22830. doi:10.1074/jbc.M412547200 - PubMed
  14. Romani de Wit T, de Leeuw HP, Rondaij MG, et al. Von Willebrand factor targets IL-8 to Weibel-Palade bodies in an endothelial cell line. Exp Cell Res. 2003;286:67-74. doi:10.1016/s0014-4827(03)00094-6 - PubMed
  15. Pinho S, Marchand T, Yang E, Wei Q, Nerlov C, Frenette PS. Lineage-Biased Hematopoietic Stem Cells Are Regulated by Distinct Niches. Dev Cell. 2018;44:634-641 e4. doi:10.1016/j.devcel.2018.01.016 - PubMed
  16. Zhou C, Chen H, Lu F, et al. Cav3.1 (alpha1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007;292:L833-L844. doi:10.1152/ajplung.00377.2006. - PubMed
  17. Wang JW, Valentijn JA, Valentijn KM, et al. Formation of platelet-binding von Willebrand factor strings on non-endothelial cells. J Thromb Haemost. 2012;10:2168-2178. doi:10.1111/j.1538-7836.2012.04891.x - PubMed
  18. Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood. 2014;124:1412-1425. doi:10.1182/blood-2014-05-378638 - PubMed
  19. Fu H, Jiang Y, Yang D, Scheiflinger F, Wong WP, Springer TA. Flow-induced elongation of von Willebrand factor precedes tension-dependent activation. Nat Commun. 2017;8:324. doi:10.1038/s41467-017-00230-2 - PubMed
  20. Muller JP, Mielke S, Lof A, et al. Force sensing by the vascular protein von Willebrand factor is tuned by a strong intermonomer interaction. Proc Natl Acad Sci USA. 2016;113:1208-1213. doi:10.1073/pnas.1516214113 - PubMed
  21. Aponte-Santamaria C, Huck V, Posch S, et al. Force-sensitive autoinhibition of the von Willebrand factor is mediated by interdomain interactions. Biophys J. 2015;108:2312-2321. doi:10.1016/j.bpj.2015.03.041 - PubMed
  22. Springer TA. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost. 2011;9(Suppl 1):130-143. doi:10.1111/j.1538-7836.2011.04320.x - PubMed
  23. Ruggeri ZM. Platelet GPIb: sensing force and responding. Blood. 2015;125:423-424. doi:10.1182/blood-2014-12-610642 - PubMed
  24. Zhang W, Deng W, Zhou L, et al. Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. Blood. 2015;125:562-569. doi:10.1182/blood-2014-07-589507 - PubMed
  25. Deng W, Xu Y, Chen W, et al. Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nat Commun. 2016;7:12863. doi:10.1038/ncomms12863 - PubMed
  26. Quach ME, Syed AK, Li R. A uniform shear assay for human platelet and cell surface receptors via cone-plate viscometry. J vis Exp. 2019;148. doi:10.3791/59704 - PubMed
  27. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24:123-134. doi:10.1016/j.blre.2010.03.003 - PubMed
  28. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood. 1998;91:2032-2044. - PubMed
  29. Cooney KA, Ginsburg D. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Blood. 1996;87:2322-2328. - PubMed
  30. Yee A, Gildersleeve RD, Gu S, et al. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014;124:445-452. doi:10.1182/blood-2013-11-540534 - PubMed
  31. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia. 2010;16:3-13. doi:10.1111/j.1365-2516.2009.02005.x - PubMed
  32. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262:8443-8446. - PubMed
  33. Jorieux S, Magallon T, Mazurier C. Evidence that NH2-terminal but not COOH-terminal moiety of plasma von Willebrand factor binds to factor VIII. Thromb Res. 1987;48:205-210. doi:10.1016/0049-3848(87)90417-8 - PubMed
  34. Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood. 1987;70:1679-1682. - PubMed
  35. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118:3212-3221. doi:10.1182/blood-2011-02-306597 - PubMed
  36. Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost. 2009;7:2088-2095. doi:10.1111/j.1538-7836.2009.03620.x - PubMed
  37. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem. 2005;280:21773-21778. doi:10.1074/jbc.M502529200 - PubMed
  38. Nishida N, Sumikawa H, Sakakura M, et al. Collagen-binding mode of vWF-A3 domain determined by a transferred cross-saturation experiment. Nat Struct Biol. 2003;10:53-58. doi:10.1038/nsb876 - PubMed
  39. Romijn RA, Westein E, Bouma B, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem. 2003;278:15035-15039. doi:10.1074/jbc.M208977200 - PubMed
  40. Romijn RA, Bouma B, Wuyster W, et al. Identification of the collagen-binding site of the von Willebrand factor A3-domain. J Biol Chem. 2001;276:9985-9991. doi:10.1074/jbc.M006548200 - PubMed
  41. Flood VH, Gill JC, Christopherson PA, et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost. 2012;10:1425-1432. doi:10.1111/j.1538-7836.2012.04747.x - PubMed
  42. Xu ER, von Bulow S, Chen PC, et al. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor. Blood. 2019;133:366-376. doi:10.1182/blood-2018-04-843615 - PubMed
  43. Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012;119:4543-4553. doi:10.1182/blood-2011-06-360875 - PubMed
  44. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010;8:1431-1433. doi:10.1111/j.1538-7836.2010.03869.x - PubMed
  45. Slobodianuk TL, Kochelek C, Foeckler J, Kalloway S, Weiler H, Flood VH. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding. J Thromb Haemost. 2019;17:63-71. doi:10.1111/jth.14341 - PubMed
  46. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279:12102-12109. doi:10.1074/jbc.M310436200 - PubMed
  47. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112:1704-1712. doi:10.1182/blood-2008-01-133181 - PubMed
  48. Tsoupras A, Zabetakis I, Lordan R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function. MethodsX. 2019;6:63-70. doi:10.1016/j.mex.2018.12.012 - PubMed
  49. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost. 2000;83:127-135. - PubMed
  50. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology. 1997;29:385-391. doi:10.1080/00313029700169365 - PubMed
  51. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis. 1991;2:285-291. doi:10.1097/00001721-199104000-00011 - PubMed
  52. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244. - PubMed
  53. Hassenpflug WA, Budde U, Obser T, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood. 2006;107:2339-2345. doi:10.1182/blood-2005-04-1758 - PubMed
  54. Zhou YF, Eng ET, Nishida N, Lu C, Walz T, Springer TA. A pH-regulated dimeric bouquet in the structure of von Willebrand factor. EMBO J. 2011;30:4098-4111. doi:10.1038/emboj.2011.297 - PubMed
  55. Deng W, Voos KM, Colucci JK, et al. Delimiting the autoinhibitory module of von Willebrand factor. J Thromb Haemost. 2018;16:2097-2105. doi:10.1111/jth.14251 - PubMed
  56. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost. 2007;5:1363-1370. doi:10.1111/j.1538-7836.2007.02536.x - PubMed
  57. Arce NA, Cao W, Brown AK, et al. Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module. Nat Commun. 2021;12:2360. doi:10.1038/s41467-021-22634-x - PubMed
  58. Deng W, Wang Y, Druzak SA, et al. A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor. J Thromb Haemost. 2017;15:1867-1877. doi:10.1111/jth.13775 - PubMed
  59. Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128:2007-2016. doi:10.1182/blood-2016-04-713289 - PubMed
  60. Michiels JJ, van Vliet HH, Berneman Z, et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost. 2007;13:14-34. doi:10.1177/1076029606296399 - PubMed
  61. Casonato A, Daidone V, Padrini R. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. Semin Thromb Hemost. 2011;37:456-463. doi:10.1055/s-0031-1281029 - PubMed
  62. Rand JH, Badimon L, Gordon RE, Uson RR, Fuster V. Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location. Arteriosclerosis. 1987;7:287-291. doi:10.1161/01.atv.7.3.287 - PubMed
  63. Wu QY, Drouet L, Carrier JL, et al. Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis. 1987;7:47-54. doi:10.1161/01.atv.7.1.47 - PubMed
  64. Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol. 1992;141:673-683. - PubMed
  65. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood. 1998;92:2791-2801. - PubMed
  66. Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV. Clearance of von Willebrand factor. J Thromb Haemost. 2013;11(Suppl 1):202-211. doi:10.1111/jth.12226 - PubMed
  67. Lenting PJ, Van schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5:1353-1360. doi:10.1111/j.1538-7836.2007.02572.x - PubMed

Publication Types

Grant support